BOOK
Gastrointestinal Neoplasia, An Issue of Gastroenterology Clinics of North America, E-Book
Paul J. Limburg | Dan A. Dixon
(2016)
Additional Information
Book Details
Abstract
Gastrointestinal (GI) cancers account for nearly 150,000 deaths each year, in the United States alone. Encouragingly, environmental risk factors, premalignant conditions, and high-risk familial kindreds are well described for many GI cancers. In this comprehensive volume on GI Neoplasia, all luminal cancers will be discussed, along with pancreas cancer, gastrointestinal stromal tumors (GISTs), carcinoid tumors, and neuroendocrine tumors. Hepatobiliary cancers are not addressed, as these tumors could form the basis of a separate volume. Articles are organized to address several key topics for each cancer type, such as: public health burden, molecular pathways, risk and protective factors, early detection, clinical evaluation, management, and survivorship.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| GastrointestinalNeoplasia | i | ||
| Copyright | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface: Gastrointestinal Neoplasia: Current Perspectives and Emerging Frontiers\r | vii | ||
| Esophageal Cancer\r | vii | ||
| Current Perspectives on Gastric Cancer\r | vii | ||
| Pancreatic Cancer: A Review\r | vii | ||
| Small Bowel Adenocarcinoma\r | vii | ||
| Colorectal Cancer: Genetics is Changing Everything\r | viii | ||
| Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy\r | viii | ||
| Neuroendocrine Tumors\r | viii | ||
| Heritable Gastrointestinal Cancer Syndromes\r | ix | ||
| Molecular Detection of Gastrointestinal Neoplasia: Innovations in Early Detection and Screening\r | ix | ||
| The Role of the Microbiome in Gastrointestinal Cancer\r | ix | ||
| GASTROENTEROLOGY\rCLINICS OF NORTH AMERICA | x | ||
| FORTHCOMING ISSUES | x | ||
| December 2016 | x | ||
| March 2017 | x | ||
| June 2017 | x | ||
| September 2017 | x | ||
| RECENT ISSUES | x | ||
| June 2016 | x | ||
| March 2016 | x | ||
| December 2015 | x | ||
| September 2015 | x | ||
| Preface:\rGastrointestinal Neoplasia: Current Perspectives and Emerging Frontiers | xi | ||
| REFERENCES | xii | ||
| Esophageal Cancer | 399 | ||
| Key points | 399 | ||
| INTRODUCTION | 399 | ||
| SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS | 400 | ||
| Current Perspectives on Gastric Cancer | 413 | ||
| Key points | 413 | ||
| GLOBAL IMPACT OF GASTRIC CANCER | 413 | ||
| GASTRIC CANCER CAUSES AND RISK FACTORS | 414 | ||
| Infectious Agents Associated with Gastric Cancer | 414 | ||
| Helicobacter pylori | 414 | ||
| Epstein-Barr virus | 415 | ||
| Genetic Predisposition: Familial Gastric Cancer | 416 | ||
| Demographic, Environmental, and Lifestyle Risk Factors | 416 | ||
| GASTRIC CANCER CLASSIFICATION | 416 | ||
| Histologic Classification | 417 | ||
| GASTRIC CANCER PREVENTION | 418 | ||
| Lifestyle Modification | 418 | ||
| Chemoprevention | 419 | ||
| Helicobacter pylori Eradication | 419 | ||
| SCREENING AND SURVEILLANCE | 419 | ||
| DIAGNOSTIC EVALUATION | 421 | ||
| CLINICAL MANAGEMENT | 421 | ||
| PROGNOSIS AND SURVIVORSHIP | 422 | ||
| ACKNOWLEDGMENTS | 422 | ||
| REFERENCES | 422 | ||
| Pancreatic Cancer | 429 | ||
| Key points | 429 | ||
| INTRODUCTION AND PUBLIC HEALTH CONCERNS | 429 | ||
| MOLECULAR PATHWAYS/GENETICS | 430 | ||
| RISK FACTORS | 432 | ||
| EARLY DETECTION | 433 | ||
| DIAGNOSTIC EVALUATION | 435 | ||
| CLINICAL MANAGEMENT | 435 | ||
| SURGERY | 437 | ||
| CHEMOTHERAPY | 439 | ||
| SURVIVORSHIP | 439 | ||
| FUTURE DIRECTIONS | 440 | ||
| SUMMARY | 441 | ||
| REFERENCES | 441 | ||
| Small Bowel Adenocarcinoma | 447 | ||
| Key points | 447 | ||
| INTRODUCTION | 447 | ||
| EPIDEMIOLOGY | 448 | ||
| Small Intestine Cancer | 448 | ||
| Small Bowel Adenocarcinoma | 448 | ||
| Duodenum Adenocarcinoma | 448 | ||
| TUMOR PHENOTYPING | 448 | ||
| Wnt/Adenomatous polyposis coli /β-Catenin Signaling Pathway | 448 | ||
| Adenomatous polyposis coli | 448 | ||
| Nuclear accumulation of β-catenin | 448 | ||
| Other Tumor Phenotyping | 450 | ||
| Vascular endothelial growth factor and epidermal growth factor receptor | 450 | ||
| RAS | 450 | ||
| HER2 | 450 | ||
| TP53 | 450 | ||
| Mismatch Repair Alteration | 450 | ||
| RISK FACTORS FOR SMALL BOWEL ADENOCARCINOMA | 450 | ||
| Genetic Predisposition | 450 | ||
| Familial adenomatous polyposis | 450 | ||
| Lynch syndrome | 450 | ||
| Peutz-Jeghers syndrome | 451 | ||
| Intestinal Diseases | 451 | ||
| Crohn’s disease | 451 | ||
| Celiac disease | 451 | ||
| Environmental Factors | 451 | ||
| DIAGNOSIS OF SMALL BOWEL ADENOCARCINOMA | 451 | ||
| Computed Tomography with Enteroclysis | 451 | ||
| Video Capsule Endoscopy | 451 | ||
| Double Balloon Enteroscopy | 451 | ||
| PROGNOSIS | 452 | ||
| Lymph Node | 452 | ||
| Duodenal Primary Tumors | 452 | ||
| Biologic Factors | 452 | ||
| Metastatic Small Bowel Adenocarcinoma | 452 | ||
| TREATMENT | 452 | ||
| Localized Cancer | 452 | ||
| Surgical resection | 452 | ||
| Adjuvant chemotherapy | 452 | ||
| Metastatic Disease | 453 | ||
| Surgical treatment | 453 | ||
| Palliative chemotherapy | 453 | ||
| Targeted therapies | 454 | ||
| SUMMARY | 454 | ||
| REFERENCES | 454 | ||
| Colorectal Cancer | 459 | ||
| Key points | 459 | ||
| INTRODUCTION | 459 | ||
| MOLECULAR PATHWAYS | 460 | ||
| PUBLIC HEALTH BURDEN | 461 | ||
| Impact of Genetics on Colorectal Cancer Burden | 463 | ||
| RISK AND PROTECTIVE FACTORS | 463 | ||
| Impact of Genetics | 463 | ||
| SCREENING AND EARLY DETECTION | 464 | ||
| Impact of Genetics on Colorectal Cancer Screening | 466 | ||
| DIAGNOSTIC EVALUATION | 466 | ||
| Impact of Genetics on Colorectal Cancer Diagnosis | 468 | ||
| PROGNOSIS | 468 | ||
| Impact of Genetics | 468 | ||
| CLINICAL MANAGEMENT | 468 | ||
| Impact of Genetics | 469 | ||
| SURVIVORSHIP | 470 | ||
| Impact of Genetics | 471 | ||
| REFERENCES | 471 | ||
| Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy | 477 | ||
| Key points | 477 | ||
| INTRODUCTION | 477 | ||
| CASE SERIES FROM THE ERA BEFORE IMATINIB THERAPY | 478 | ||
| SELECTED TRIALS OF ADJUVANT IMATINIB | 479 | ||
| Z9000 (1-YEAR IMATINIB) | 479 | ||
| Z9001 (0 VS 1-YEAR ADJUVANT IMATINIB) | 480 | ||
| EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER INTERGROUP TRIAL (0 VS 2-YEAR ADJUVANT IMATINIB) | 480 | ||
| SCANDINAVIAN SARCOMA GROUP XVIII/ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE (1- VS 3-YEAR ADJUVANT IMATINIB) | 480 | ||
| ONGOING ADJUVANT TRIALS | 481 | ||
| NEOADJUVANT THERAPY | 481 | ||
| REIMAGING | 481 | ||
| MUTATIONS TO IMATINIB | 482 | ||
| NATIONAL AND INTERNATIONAL GUIDELINES | 482 | ||
| COMMENTARY | 482 | ||
| REFERENCES | 484 | ||
| Neuroendocrine Tumors | 487 | ||
| Key points | 487 | ||
| INTRODUCTION | 487 | ||
| Epidemiology | 488 | ||
| Genetics | 488 | ||
| CLINICAL PRESENTATIONS OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS | 489 | ||
| Small Bowel | 489 | ||
| Rectum | 490 | ||
| Stomach | 490 | ||
| Pancreas | 490 | ||
| DIAGNOSTIC MODALITIES | 491 | ||
| Anatomic Imaging | 491 | ||
| Functional Imaging | 491 | ||
| MARKERS OF NEUROENDOCRINE TUMORS DISEASE | 492 | ||
| Chromogranin A | 492 | ||
| Serotonin and 5-Hydroxyindoleacetic Acid | 493 | ||
| MANAGEMENT | 494 | ||
| Surgery for Primary Neuroendocrine Tumors | 494 | ||
| Liver-directed Therapies | 494 | ||
| Locoablative therapy for hepatic metastases | 494 | ||
| Hepatic artery embolization | 495 | ||
| Selective internal radiation therapy | 495 | ||
| Medical Therapies for Neuroendocrine Tumors | 495 | ||
| Somatostatin analogues | 495 | ||
| Interferon-α | 497 | ||
| Chemotherapy | 497 | ||
| Peptide receptor radionuclide therapy | 497 | ||
| Everolimus | 499 | ||
| Sunitinib | 499 | ||
| SUMMARY | 499 | ||
| REFERENCES | 500 | ||
| Heritable Gastrointestinal Cancer Syndromes | 509 | ||
| Key points | 509 | ||
| GENES AND CANCER | 509 | ||
| COLORECTAL CANCER | 511 | ||
| Lynch Syndrome | 512 | ||
| Diagnosis | 512 | ||
| Tumor screening | 514 | ||
| Management | 514 | ||
| COLONIC POLYPOSIS SYNDROMES | 514 | ||
| Familial Adenomatous Polyposis | 514 | ||
| Diagnosis | 516 | ||
| Management | 516 | ||
| MUTYH-Associated Polyposis | 517 | ||
| Polymerase Proofreading Associated Polyposis | 517 | ||
| Hamartomatous Polyposis Syndromes | 517 | ||
| Juvenile polyposis syndrome | 518 | ||
| Peutz-Jeghers syndrome | 518 | ||
| Cowden syndrome | 518 | ||
| Serrated Polyposis | 518 | ||
| Familial Colorectal Cancer Type X | 519 | ||
| Other Genetic Syndromes Associated with Colorectal Cancer Type Risk | 519 | ||
| GASTRIC CANCER | 519 | ||
| Hereditary Diffuse Gastric Cancer | 520 | ||
| Diagnosis | 520 | ||
| Management | 520 | ||
| PANCREATIC ADENOCARCINOMA | 521 | ||
| Diagnosis | 521 | ||
| Management | 521 | ||
| CLINICAL APPROACH TO GENETIC RISK ASSESSMENT FOR GASTROINTESTINAL CANCER RISK | 522 | ||
| REFERENCES | 523 | ||
| Molecular Detection of Gastrointestinal Neoplasia | 529 | ||
| Key points | 529 | ||
| INTRODUCTION | 529 | ||
| MECHANISMS, MEDIA, AND MARKERS | 530 | ||
| Whole Tumor Cells | 530 | ||
| Proteins | 531 | ||
| RNA | 531 | ||
| DNA | 532 | ||
| A GLIMPSE AT EMERGENT AND EXPERIMENTAL NEW MOLECULAR TOOLS FOR GASTROINTESTINAL CANCER SCREENING | 532 | ||
| Esophageal Cancer | 532 | ||
| Sponge-on-string device | 532 | ||
| Gastric Cancer | 534 | ||
| Gastric lavage | 534 | ||
| Pancreatic Cancer | 534 | ||
| Pancreatic juice | 534 | ||
| Cyst fluid | 534 | ||
| Blood | 535 | ||
| Stool | 535 | ||
| Hepatobiliary Cancers | 535 | ||
| Stricture brushing | 535 | ||
| Cancer screening | 536 | ||
| Colorectal Cancer | 536 | ||
| Multitarget stool DNA test | 536 | ||
| Stool DNA testing for dysplasia surveillance in inflammatory bowel disease | 537 | ||
| Blood | 537 | ||
| Universal Gastrointestinal Cancer Detection | 537 | ||
| SUMMARY | 538 | ||
| REFERENCES | 538 | ||
| The Role of the Microbiome in Gastrointestinal Cancer | 543 | ||
| Key points | 543 | ||
| INTRODUCTION | 543 | ||
| GASTRIC CANCER | 544 | ||
| HELICOBACTER PYLORI | 544 | ||
| BACTERIAL AND HOST FACTORS AFFECTING THE PROPENSITY TOWARD GASTRIC CANCER | 544 | ||
| THE STOMACH MICROBIOTA IN GASTRIC PATHOGENESIS | 545 | ||
| ANIMAL MODELS TO STUDY THE MICROBIOME AND GASTRIC CANCER | 546 | ||
| ESOPHAGEAL ADENOCARCINOMA AND THE MICROBIOME | 547 | ||
| COLORECTAL CANCER | 547 | ||
| THE MICROBIOME IN PATIENTS WITH COLONIC POLYPS OR COLORECTAL CANCER | 548 | ||
| DIET AND MICROBIAL METABOLITES | 548 | ||
| ANIMAL MODELS | 552 | ||
| SUMMARY | 552 | ||
| REFERENCES | 553 | ||
| Index | 557 |